1
|
Khalil MH. Environmental enrichment: a systematic review on the effect of a changing spatial complexity on hippocampal neurogenesis and plasticity in rodents, with considerations for translation to urban and built environments for humans. Front Neurosci 2024; 18:1368411. [PMID: 38919908 PMCID: PMC11196820 DOI: 10.3389/fnins.2024.1368411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2024] [Accepted: 05/21/2024] [Indexed: 06/27/2024] Open
Abstract
Introduction Hippocampal neurogenesis is critical for improving learning, memory, and spatial navigation. Inhabiting and navigating spatial complexity is key to stimulating adult hippocampal neurogenesis (AHN) in rodents because they share similar hippocampal neuroplasticity characteristics with humans. AHN in humans has recently been found to persist until the tenth decade of life, but it declines with aging and is influenced by environmental enrichment. This systematic review investigated the impact of spatial complexity on neurogenesis and hippocampal plasticity in rodents, and discussed the translatability of these findings to human interventions. Methods Comprehensive searches were conducted on three databases in English: PubMed, Web of Science, and Scopus. All literature published until December 2023 was screened and assessed for eligibility. A total of 32 studies with original data were included, and the process is reported in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement and checklist. Results The studies evaluated various models of spatial complexity in rodents, including environmental enrichment, changes to in-cage elements, complex layouts, and navigational mazes featuring novelty and intermittent complexity. A regression equation was formulated to synthesize key factors influencing neurogenesis, such as duration, physical activity, frequency of changes, diversity of complexity, age, living space size, and temperature. Conclusion Findings underscore the cognitive benefits of spatial complexity interventions and inform future translational research from rodents to humans. Home-cage enrichment and models like the Hamlet complex maze and the Marlau cage offer insight into how architectural design and urban navigational complexity can impact neurogenesis in humans. In-space changing complexity, with and without physical activity, is effective for stimulating neurogenesis. While evidence on intermittent spatial complexity in humans is limited, data from the COVID-19 pandemic lockdowns provide preliminary evidence. Existing equations relating rodent and human ages may allow for the translation of enrichment protocol durations from rodents to humans.
Collapse
|
2
|
Wijnen K, Genzel L, van der Meij J. Rodent maze studies: from following simple rules to complex map learning. Brain Struct Funct 2024; 229:823-841. [PMID: 38488865 PMCID: PMC11004052 DOI: 10.1007/s00429-024-02771-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2023] [Accepted: 01/30/2024] [Indexed: 03/17/2024]
Abstract
More than 100 years since the first maze designed for rodent research, researchers now have the choice of a variety of mazes that come in many different shapes and sizes. Still old designs get modified and new designs are introduced to fit new research questions. Yet, which maze is the most optimal to use or which training paradigm should be applied, remains up for debate. In this review, we not only provide a historical overview of maze designs and usages in rodent learning and memory research, but also discuss the possible navigational strategies the animals can use to solve each maze. Furthermore, we summarize the different phases of learning that take place when a maze is used as the experimental task. At last, we delve into how training and maze design can affect what the rodents are actually learning in a spatial task.
Collapse
Affiliation(s)
- Kjell Wijnen
- Donders Institute for Brain, Cognition and Behaviour, Radboud University, Postbus 9010, 6500 GL, Nijmegen, The Netherlands
| | - Lisa Genzel
- Donders Institute for Brain, Cognition and Behaviour, Radboud University, Postbus 9010, 6500 GL, Nijmegen, The Netherlands.
| | - Jacqueline van der Meij
- Donders Institute for Brain, Cognition and Behaviour, Radboud University, Postbus 9010, 6500 GL, Nijmegen, The Netherlands.
| |
Collapse
|
3
|
Godoy R, Macedo AB, Gervazio KY, Ribeiro LR, Lima JLF, Salvadori MGSS. Effects of ortho-eugenol on anxiety, working memory and oxidative stress in mice. BRAZ J BIOL 2023; 83:e271785. [PMID: 37610945 DOI: 10.1590/1519-6984.271785] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2023] [Accepted: 06/21/2023] [Indexed: 08/25/2023] Open
Abstract
Ortho-eugenol is a synthetic derivative from eugenol, the major compound of clove essential oil, which has demonstrated antidepressant and antinociceptive effects in pioneering studies. Additionally, its effects appear to be dependent on the noradrenergic and dopaminergic systems. Depression and anxiety disorders are known to share a great overlap in their pathophysiology, and many drugs are effective in the treatment of both diseases. Furthermore, high levels of anxiety are related to working memory deficits and increased oxidative stress. Thus, in this study we investigated the effects of acute treatment of ortho-eugenol, at 50, 75 and 100 mg/kg, on anxiety, working memory and oxidative stress in male Swiss mice. Our results show that the 100 mg/kg dose increased the number of head-dips and reduced the latency in the hole-board test. The 50 mg/kg dose reduced malondialdehyde levels in the prefrontal cortex and the number of Y-maze entries compared to the MK-801-induced hyperlocomotion group. All doses reduced nitrite levels in the hippocampus. It was also possible to assess a statistical correlation between the reduction of oxidative stress and hyperlocomotion after the administration of ortho-eugenol. However, acute treatment was not able to prevent working memory deficits. Therefore, the present study shows that ortho-eugenol has an anxiolytic and antioxidant effect, and was able to prevent substance-induced hyperlocomotion. Our results contribute to the elucidation of the pharmacological profile of ortho-eugenol, as well as to direct further studies that seek to investigate its possible clinical applications.
Collapse
Affiliation(s)
- R Godoy
- Universidade Federal da Paraíba, Instituto de Pesquisa em Fármacos e Medicamentos, Laboratório de Psicofarmacologia, João Pessoa, PB, Brasil
| | - A B Macedo
- Universidade Federal da Paraíba, Instituto de Pesquisa em Fármacos e Medicamentos, Laboratório de Psicofarmacologia, João Pessoa, PB, Brasil
| | - K Y Gervazio
- Universidade Federal da Paraíba, Instituto de Pesquisa em Fármacos e Medicamentos, Laboratório de Psicofarmacologia, João Pessoa, PB, Brasil
- Universidade Federal da Paraíba, Centro de Ciências da Saúde, Programa de Pós-graduação em Produtos Bioativos Naturais e Sintéticos - PgPNSB, João Pessoa, PB, Brasil
| | - L R Ribeiro
- Universidade Federal da Paraíba, Instituto de Pesquisa em Fármacos e Medicamentos, Laboratório de Psicofarmacologia, João Pessoa, PB, Brasil
| | - J L F Lima
- Universidade Federal da Paraíba, Instituto de Pesquisa em Fármacos e Medicamentos, Laboratório de Psicofarmacologia, João Pessoa, PB, Brasil
- Universidade Federal da Paraíba, Centro de Ciências da Saúde, Programa de Pós-graduação em Produtos Bioativos Naturais e Sintéticos - PgPNSB, João Pessoa, PB, Brasil
| | - M G S S Salvadori
- Universidade Federal da Paraíba, Instituto de Pesquisa em Fármacos e Medicamentos, Laboratório de Psicofarmacologia, João Pessoa, PB, Brasil
- Universidade Federal da Paraíba, Centro de Ciências da Saúde, Programa de Pós-graduação em Produtos Bioativos Naturais e Sintéticos - PgPNSB, João Pessoa, PB, Brasil
| |
Collapse
|
4
|
Hua J, Garcia de Paco E, Linck N, Maurice T, Desrumaux C, Manoury B, Rassendren F, Ulmann L. Microglial P2X4 receptors promote ApoE degradation and contribute to memory deficits in Alzheimer's disease. Cell Mol Life Sci 2023; 80:138. [PMID: 37145189 PMCID: PMC10163120 DOI: 10.1007/s00018-023-04784-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2023] [Revised: 04/18/2023] [Accepted: 04/19/2023] [Indexed: 05/06/2023]
Abstract
Numerous evidences support that microglia contributes to the progression of Alzheimer's disease. P2X4 receptors are ATP-gated channels with high calcium permeability, which are de novo expressed in a subset of reactive microglia associated with various pathological contexts, contributing to microglial functions. P2X4 receptors are mainly localized in lysosomes and trafficking to the plasma membrane is tightly regulated. Here, we investigated the role of P2X4 in the context of Alzheimer's disease (AD). Using proteomics, we identified Apolipoprotein E (ApoE) as a specific P2X4 interacting protein. We found that P2X4 regulates lysosomal cathepsin B (CatB) activity promoting ApoE degradation; P2rX4 deletion results in higher amounts of intracellular and secreted ApoE in both bone-marrow-derived macrophage (BMDM) and microglia from APPswe/PSEN1dE9 brain. In both human AD brain and APP/PS1 mice, P2X4 and ApoE are almost exclusively expressed in plaque-associated microglia. In 12-month-old APP/PS1 mice, genetic deletion of P2rX4 reverses topographical and spatial memory impairment and reduces amount of soluble small aggregates of Aß1-42 peptide, while no obvious alteration of plaque-associated microglia characteristics is observed. Our results support that microglial P2X4 promotes lysosomal ApoE degradation, indirectly altering Aß peptide clearance, which in turn might promotes synaptic dysfunctions and cognitive deficits. Our findings uncover a specific interplay between purinergic signaling, microglial ApoE, soluble Aß (sAß) species and cognitive deficits associated with AD.
Collapse
Affiliation(s)
- Jennifer Hua
- IGF, Univ Montpellier, CNRS, INSERM, Montpellier, France
- LabEx Ion Channel Science and Therapeutics, Montpellier, France
| | - Elvira Garcia de Paco
- IGF, Univ Montpellier, CNRS, INSERM, Montpellier, France
- LabEx Ion Channel Science and Therapeutics, Montpellier, France
| | - Nathalie Linck
- IGF, Univ Montpellier, CNRS, INSERM, Montpellier, France
- LabEx Ion Channel Science and Therapeutics, Montpellier, France
| | - Tangui Maurice
- MMDN, Univ Montpellier, EPHE, INSERM, Montpellier, France
| | | | - Bénédicte Manoury
- Institut Necker Enfants Malades, INSERM, CNRS, Université de Paris, Paris, France
| | - François Rassendren
- IGF, Univ Montpellier, CNRS, INSERM, Montpellier, France
- LabEx Ion Channel Science and Therapeutics, Montpellier, France
| | - Lauriane Ulmann
- IGF, Univ Montpellier, CNRS, INSERM, Montpellier, France.
- LabEx Ion Channel Science and Therapeutics, Montpellier, France.
| |
Collapse
|
5
|
Canet G, Zussy C, Hernandez C, Maurice T, Desrumaux C, Givalois L. The pathomimetic oAβ25–35 model of Alzheimer's disease: Potential for screening of new therapeutic agents. Pharmacol Ther 2023; 245:108398. [PMID: 37001735 DOI: 10.1016/j.pharmthera.2023.108398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2023] [Accepted: 03/27/2023] [Indexed: 03/31/2023]
Abstract
Alzheimer's disease (AD) is the most common form of dementia in the elderly, currently affecting more than 40 million people worldwide. The two main histopathological hallmarks of AD were identified in the 1980s: senile plaques (composed of aggregated amyloid-β (Aβ) peptides) and neurofibrillary tangles (composed of hyperphosphorylated tau protein). In the human brain, both Aβ and tau show aggregation into soluble and insoluble oligomers. Soluble oligomers of Aβ include their most predominant forms - Aβ1-40 and Aβ1-42 - as well as shorter peptides such as Aβ25-35 or Aβ25-35/40. Most animal models of AD have been developed using transgenesis, based on identified human mutations. However, these familial forms of AD represent less than 1% of AD cases. In this context, the idea emerged in the 1990s to directly inject the Aβ25-35 fragment into the rodent brain to develop an acute model of AD that could mimic the disease's sporadic forms (99% of all cases). This review aims to: (1) summarize the biological activity of Aβ25-35, focusing on its impact on the main structural and functional alterations observed in AD (cognitive deficits, APP misprocessing, tau system dysfunction, neuroinflammation, oxidative stress, cholinergic and glutamatergic alterations, HPA axis dysregulation, synaptic deficits and cell death); and (2) confirm the interest of this pathomimetic model in AD research, as it has helped identify and characterize many molecules (marketed, in clinical development, and in preclinical testing), and to the development of alternative approaches for AD prevention and therapy. Today, the Aβ25-35 model appears as a first-intent choice model to rapidly screen the symptomatic or neuroprotective potencies of new compounds, chemical series, or innovative therapeutic strategies.
Collapse
|
6
|
Spatz P, Zimmermann T, Steinmüller S, Hofmann J, Maurice T, Decker M. Novel benzimidazole-based pseudo-irreversible butyrylcholinesterase inhibitors with neuroprotective activity in an Alzheimer's disease mouse model. RSC Med Chem 2022; 13:944-954. [PMID: 36092149 PMCID: PMC9384809 DOI: 10.1039/d2md00087c] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2022] [Accepted: 05/19/2022] [Indexed: 09/17/2023] Open
Abstract
As levels of acetylcholinesterase (AChE) decrease while levels of butyrylcholinesterase (BChE) increase in later stages of Alzheimer's disease (AD), BChE stands out as a promising target for treatment of AD. Therefore, several benzimidazole-carbamates were designed based on docking studies to inhibit BChE selectively over AChE, while retaining a reasonable solubility. Synthesized molecules exhibit IC50 values from 2.4 μM down to 3.7 nM with an overall highly hBChE-selective profile of the designed compound class. After evaluation of potential neurotoxicity, the most promising compound was further investigated in vivo. Compound 11d attenuates Aβ25-35-induced learning impairments in both spontaneous alternation and passive avoidance responses at a very low dosage of 0.03 mg kg-1, proving selective BChE inhibition to lead to effective neuroprotectivity in AD.
Collapse
Affiliation(s)
- Philipp Spatz
- Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy and Food Chemistry, Julius Maximilian University of Würzburg Am Hubland D-97074 Germany
| | - Thomas Zimmermann
- Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy and Food Chemistry, Julius Maximilian University of Würzburg Am Hubland D-97074 Germany
| | - Sophie Steinmüller
- Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy and Food Chemistry, Julius Maximilian University of Würzburg Am Hubland D-97074 Germany
| | - Julian Hofmann
- Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy and Food Chemistry, Julius Maximilian University of Würzburg Am Hubland D-97074 Germany
| | - Tangui Maurice
- MMDN, University of Montpellier, EPHE, INSERM F-34095 Montpellier France
| | - Michael Decker
- Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy and Food Chemistry, Julius Maximilian University of Würzburg Am Hubland D-97074 Germany
| |
Collapse
|
7
|
Nicolas S, McGovern AJ, Hueston CM, O'Mahony SM, Cryan JF, O'Leary OF, Nolan YM. Prior maternal separation stress alters the dendritic complexity of new hippocampal neurons and neuroinflammation in response to an inflammatory stressor in juvenile female rats. Brain Behav Immun 2022; 99:327-338. [PMID: 34732365 DOI: 10.1016/j.bbi.2021.10.016] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/30/2021] [Revised: 10/19/2021] [Accepted: 10/23/2021] [Indexed: 12/11/2022] Open
Abstract
Stress during critical periods of neurodevelopment is associated with an increased risk of developing stress-related psychiatric disorders, which are more common in women than men. Hippocampal neurogenesis (the birth of new neurons) is vulnerable to maternal separation (MS) and inflammatory stressors, and emerging evidence suggests that hippocampal neurogenesis is more sensitive to stress in the ventral hippocampus (vHi) than in the dorsal hippocampus (dHi). Although research into the effects of MS stress on hippocampal neurogenesis is well documented in male rodents, the effect in females remains underexplored. Similarly, reports on the impact of inflammatory stressors on hippocampal neurogenesis in females are limited, especially when female bias in the prevalence of stress-related psychiatric disorders begins to emerge. Thus, in this study we investigated the effects of MS followed by an inflammatory stressor (lipopolysaccharide, LPS) in early adolescence on peripheral and hippocampal inflammatory responses and hippocampal neurogenesis in juvenile female rats. We show that MS enhanced an LPS-induced increase in the pro-inflammatory cytokine IL-1β in the vHi but not in the dHi. However, microglial activation was similar following LPS alone or MS alone in both hippocampal regions, while MS prior to LPS reduced microglial activation in both dHi and vHi. The production of new neurons was unaffected by MS and LPS. MS and LPS independently reduced the dendritic complexity of new neurons, and MS exacerbated LPS-induced reductions in the complexity of distal dendrites of new neurons in the vHi but not dHi. These data highlight that MS differentially primes the physiological response to LPS in the juvenile female rat hippocampus.
Collapse
Affiliation(s)
- Sarah Nicolas
- Department of Anatomy and Neuroscience, University College Cork, Ireland
| | - Andrew J McGovern
- Department of Anatomy and Neuroscience, University College Cork, Ireland
| | - Cara M Hueston
- Department of Anatomy and Neuroscience, University College Cork, Ireland
| | - Siobhain M O'Mahony
- Department of Anatomy and Neuroscience, University College Cork, Ireland; APC Microbiome Ireland, University College Cork, Ireland
| | - John F Cryan
- Department of Anatomy and Neuroscience, University College Cork, Ireland; APC Microbiome Ireland, University College Cork, Ireland
| | - Olivia F O'Leary
- Department of Anatomy and Neuroscience, University College Cork, Ireland; APC Microbiome Ireland, University College Cork, Ireland
| | - Yvonne M Nolan
- Department of Anatomy and Neuroscience, University College Cork, Ireland; APC Microbiome Ireland, University College Cork, Ireland.
| |
Collapse
|
8
|
Couly S, Carles A, Denus M, Benigno-Anton L, Maschat F, Maurice T. Exposure of R6/2 mice in an enriched environment augments P42 therapy efficacy on Huntington's disease progression. Neuropharmacology 2021; 186:108467. [PMID: 33516737 DOI: 10.1016/j.neuropharm.2021.108467] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2020] [Revised: 01/11/2021] [Accepted: 01/14/2021] [Indexed: 11/30/2022]
Abstract
Huntington's disease (HD) is due to a mutation in the gene encoding for Huntingtin protein generating polyQ domain extension. Mutant Htt (mHtt) leads to important dysfunction of the BDNF/TrkB signaling. We previously described the 23aa Htt fragment P42, that attenuated the pathological phenotypes induced by mHtt. We reported that, in the R6/2 mouse model of HD, P42 rescued striatal TrkB level but marginally increased cortical BDNF. In the present study, our aim was to address P42 neuroprotection in presence of an external input of BDNF. We combined P42 administration with environmental enrichment (EE), induced by training in the Hamlet test. We examined the consequences of P42 + EE combination on different phenotypes in R6/2 HD mice: motor and cognitive performances, recorded at early and late pathological stages, and analyzed aggregated mHtt and BDNF levels in forebrain structures. Hamlet exploration (i.e., entries in Run, Hide, Eat, Drink and Interact houses) was gradually impaired in R6/2 mice, but maintained by P42 treatment until week 8. Topographic memory alteration measured at week 7 was attenuated by P42. Motor performances (rotarod) were significantly ameliorated by the P42 + EE combination until late stage (week 12). The P42 + EE combination also significantly decreased aggregated Htt levels in the hippocampus, striatum and cortex, and increased BDNF levels in the cortex and striatum. We concluded that combination between P42 treatment, known to increase TrkB striatal expression, and a BDNF-enhancing therapy such as EE efficiently delayed HD pathology in R6/2 mice. Use of dual therapies might be a pertinent strategy to fight neurodegeneration in HD.
Collapse
Affiliation(s)
- Simon Couly
- MMDN, Univ Montpellier, EPHE, INSERM, Montpellier, France
| | - Allison Carles
- MMDN, Univ Montpellier, EPHE, INSERM, Montpellier, France
| | - Morgane Denus
- MMDN, Univ Montpellier, EPHE, INSERM, Montpellier, France
| | | | | | - Tangui Maurice
- MMDN, Univ Montpellier, EPHE, INSERM, Montpellier, France.
| |
Collapse
|
9
|
Crouzier L, Couly S, Roques C, Peter C, Belkhiter R, Arguel Jacquemin M, Bonetto A, Delprat B, Maurice T. Sigma-1 (σ 1) receptor activity is necessary for physiological brain plasticity in mice. Eur Neuropsychopharmacol 2020; 39:29-45. [PMID: 32893057 DOI: 10.1016/j.euroneuro.2020.08.010] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/08/2020] [Revised: 07/24/2020] [Accepted: 08/25/2020] [Indexed: 12/14/2022]
Abstract
The sigma-1 receptor (S1R) is a membrane-associated protein expressed in neurons and glia at mitochondria-associated endoplasmic reticulum (ER) membranes (MAMs). S1R interacts with different partners to regulate cellular responses, including ER stress, mitochondrial physiology and Ca2+ fluxes. S1R shapes cellular plasticity by directly modulating signaling pathways involved in inflammatory responses, cell survival and death. We here analyzed its impact on brain plasticity in vivo, in mice trained in a complex maze, the Hamlet test. The device, providing strong enriched environment (EE) conditions, mimics a small village. It has a central agora and streets expanding from it, leading to functionalized houses where animals can Drink, Eat, Hide, Run, or Interact. Animals were trained in groups, 4 h/day for two weeks, and their maze exploration and topographic memory could be analyzed. Several groups of mice were considered: non-trained vs. trained; repeatedly administered with saline vs. NE-100, a selective S1R antagonist; and wildtype vs. S1R KO mice. S1R inactivation altered maze exploration and prevented topographic learning. EE induced a strong plasticity measured through resilience to behavioral despair or to the amnesic effects of scopolamine, and increases in S1R expression and bdnf mRNA levels in the hippocampus; increases in neurogenesis (proliferation and maturation); and increases of histone acetylation in the hippocampus and cortex. S1R inactivation altered all these parameters significantly, showing that S1R activity plays a major role in physiological brain plasticity. As S1R is a major resident protein in MAMs, modulating ER responses and mitochondrial homeostasy, MAM physiology appeared impacted by enriched environment.
Collapse
Affiliation(s)
- Lucie Crouzier
- MMDN, Univ Montpellier, EPHE, INSERM, Montpellier, France
| | - Simon Couly
- MMDN, Univ Montpellier, EPHE, INSERM, Montpellier, France
| | - Chloé Roques
- MMDN, Univ Montpellier, EPHE, INSERM, Montpellier, France
| | - Coralie Peter
- MMDN, Univ Montpellier, EPHE, INSERM, Montpellier, France
| | | | | | - Anna Bonetto
- MMDN, Univ Montpellier, EPHE, INSERM, Montpellier, France
| | | | - Tangui Maurice
- MMDN, Univ Montpellier, EPHE, INSERM, Montpellier, France.
| |
Collapse
|
10
|
Couly S, Denus M, Bouchet M, Rubinstenn G, Maurice T. Anti-Amnesic and Neuroprotective Effects of Fluoroethylnormemantine in a Pharmacological Mouse Model of Alzheimer's Disease. Int J Neuropsychopharmacol 2020; 24:142-157. [PMID: 32977336 PMCID: PMC7883897 DOI: 10.1093/ijnp/pyaa075] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/22/2020] [Revised: 09/15/2020] [Accepted: 09/24/2020] [Indexed: 12/28/2022] Open
Abstract
BACKGROUND Current therapies in Alzheimer's disease (AD), including Memantine, have proven to be only symptomatic but not curative or disease modifying. Fluoroethylnormemantine (FENM) is a structural analogue of Memantine, functionalized with a fluorine group that allowed its use as a positron emission tomography tracer. We here analyzed FENM neuroprotective potential in a pharmacological model of AD compared with Memantine. METHODS Swiss mice were treated intracerebroventricularly with aggregated Aβ 25-35 peptide and examined after 1 week in a battery of memory tests (spontaneous alternation, passive avoidance, object recognition, place learning in the water-maze, topographic memory in the Hamlet). Toxicity induced in the mouse hippocampus or cortex was analyzed biochemically or morphologically. RESULTS Both Memantine and FENM showed symptomatic anti-amnesic effects in Aβ 25-35-treated mice. Interestingly, FENM was not amnesic when tested alone at 10 mg/kg, contrarily to Memantine. Drugs injected once per day prevented Aβ 25-35-induced memory deficits, oxidative stress (lipid peroxidation, cytochrome c release), inflammation (interleukin-6, tumor necrosis factor-α increases; glial fibrillary acidic protein and Iba1 immunoreactivity in the hippocampus and cortex), and apoptosis and cell loss (Bcl-2-associated X/B-cell lymphoma 2 ratio; cell loss in the hippocampus CA1 area). However, FENM effects were more robust than observed with Memantine, with significant attenuations vs the Aβ 25-35-treated group. CONCLUSIONS FENM therefore appeared as a potent neuroprotective drug in an AD model, with a superior efficacy compared with Memantine and an absence of direct amnesic effect at higher doses. These results open the possibility to use the compound at more relevant dosages than those actually proposed in Memantine treatment for AD.
Collapse
Affiliation(s)
- Simon Couly
- MMDN, Univ Montpellier, INSERM, EPHE, Montpellier, France
| | - Morgane Denus
- MMDN, Univ Montpellier, INSERM, EPHE, Montpellier, France
| | | | | | - Tangui Maurice
- MMDN, Univ Montpellier, INSERM, EPHE, Montpellier, France,Correspondence: Dr T. Maurice, PhD, INSERM UMR_S1198, Université de Montpellier, cc 105, Place Eugène Bataillon, 34095 Montpellier cedex 5, France ()
| |
Collapse
|
11
|
Pagnamenta AT, Heemeryck P, Martin HC, Bosc C, Peris L, Uszynski I, Gory-Fauré S, Couly S, Deshpande C, Siddiqui A, Elmonairy AA, Jayawant S, Murthy S, Walker I, Loong L, Bauer P, Vossier F, Denarier E, Maurice T, Barbier EL, Deloulme JC, Taylor JC, Blair EM, Andrieux A, Moutin MJ. Defective tubulin detyrosination causes structural brain abnormalities with cognitive deficiency in humans and mice. Hum Mol Genet 2019; 28:3391-3405. [PMID: 31363758 PMCID: PMC6891070 DOI: 10.1093/hmg/ddz186] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2019] [Revised: 07/23/2019] [Accepted: 07/23/2019] [Indexed: 12/15/2022] Open
Abstract
Reversible detyrosination of tubulin, the building block of microtubules, is crucial for neuronal physiology. Enzymes responsible for detyrosination were recently identified as complexes of vasohibins (VASHs) one or two with small VASH-binding protein (SVBP). Here we report three consanguineous families, each containing multiple individuals with biallelic inactivation of SVBP caused by truncating variants (p.Q28* and p.K13Nfs*18). Affected individuals show brain abnormalities with microcephaly, intellectual disability and delayed gross motor and speech development. Immunoblot testing in cells with pathogenic SVBP variants demonstrated that the encoded proteins were unstable and non-functional, resulting in a complete loss of VASH detyrosination activity. Svbp knockout mice exhibit drastic accumulation of tyrosinated tubulin and a reduction of detyrosinated tubulin in brain tissue. Similar alterations in tubulin tyrosination levels were observed in cultured neurons and associated with defects in axonal differentiation and architecture. Morphological analysis of the Svbp knockout mouse brains by anatomical magnetic resonance imaging showed a broad impact of SVBP loss, with a 7% brain volume decrease, numerous structural defects and a 30% reduction of some white matter tracts. Svbp knockout mice display behavioural defects, including mild hyperactivity, lower anxiety and impaired social behaviour. They do not, however, show prominent memory defects. Thus, SVBP-deficient mice recapitulate several features observed in human patients. Altogether, our data demonstrate that deleterious variants in SVBP cause this neurodevelopmental pathology, by leading to a major change in brain tubulin tyrosination and alteration of microtubule dynamics and neuron physiology.
Collapse
Affiliation(s)
- Alistair T Pagnamenta
- NIHR Oxford BRC, Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK
| | - Pierre Heemeryck
- Grenoble Institut Neurosciences, Université Grenoble Alpes, Inserm, U1216, CEA, CNRS, 38000 Grenoble, France
| | - Hilary C Martin
- Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK
| | - Christophe Bosc
- Grenoble Institut Neurosciences, Université Grenoble Alpes, Inserm, U1216, CEA, CNRS, 38000 Grenoble, France
| | - Leticia Peris
- Grenoble Institut Neurosciences, Université Grenoble Alpes, Inserm, U1216, CEA, CNRS, 38000 Grenoble, France
| | - Ivy Uszynski
- Grenoble Institut Neurosciences, Université Grenoble Alpes, Inserm, U1216, CEA, CNRS, 38000 Grenoble, France
| | - Sylvie Gory-Fauré
- Grenoble Institut Neurosciences, Université Grenoble Alpes, Inserm, U1216, CEA, CNRS, 38000 Grenoble, France
| | - Simon Couly
- MMDN, Université de Montpellier, INSERM, EPHE, UMR_S1198, Montpellier, France
| | - Charu Deshpande
- South East Thames Regional Genetics Unit, Guys and St Thomas NHS Trust, London, UK
| | - Ata Siddiqui
- Department of Neuroradiology, Kings College Hospital, Denmark Hill, London SE5 9RS, UK
| | - Alaa A Elmonairy
- Ministry of Health, Kuwait Medical Genetics Center, Sulaibikhat 80901, Kuwait
| | | | | | - Sandeep Jayawant
- Department of Paediatric Neurology, John Radcliffe Hospital, Oxford, UK
| | | | - Ian Walker
- Clinical Biochemistry, Wexham Park Hospital, Slough, UK
| | - Lucy Loong
- Oxford Centre for Genomic Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | | | - Frédérique Vossier
- Grenoble Institut Neurosciences, Université Grenoble Alpes, Inserm, U1216, CEA, CNRS, 38000 Grenoble, France
| | - Eric Denarier
- Grenoble Institut Neurosciences, Université Grenoble Alpes, Inserm, U1216, CEA, CNRS, 38000 Grenoble, France
| | - Tangui Maurice
- MMDN, Université de Montpellier, INSERM, EPHE, UMR_S1198, Montpellier, France
| | - Emmanuel L Barbier
- Grenoble Institut Neurosciences, Université Grenoble Alpes, Inserm, U1216, CEA, CNRS, 38000 Grenoble, France
| | - Jean-Christophe Deloulme
- Grenoble Institut Neurosciences, Université Grenoble Alpes, Inserm, U1216, CEA, CNRS, 38000 Grenoble, France
| | - Jenny C Taylor
- NIHR Oxford BRC, Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK
| | - Edward M Blair
- Oxford Centre for Genomic Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | - Annie Andrieux
- Grenoble Institut Neurosciences, Université Grenoble Alpes, Inserm, U1216, CEA, CNRS, 38000 Grenoble, France
| | - Marie-Jo Moutin
- Grenoble Institut Neurosciences, Université Grenoble Alpes, Inserm, U1216, CEA, CNRS, 38000 Grenoble, France
| |
Collapse
|
12
|
Crouzier L, Maurice T. Assessment of Topographic Memory in Mice in a Complex Environment Using the Hamlet Test. ACTA ACUST UNITED AC 2018; 8:e43. [DOI: 10.1002/cpmo.43] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- Lucie Crouzier
- MMDN, University of Montpellier; INSERM, EPHE, UMR-S1198 Montpellier France
| | - Tangui Maurice
- MMDN, University of Montpellier; INSERM, EPHE, UMR-S1198 Montpellier France
| |
Collapse
|